Who are CNS Stimulant's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): methylphenidate HCl (Concerta), Adderall ® Immediate Release, SODAS methylphenidate HCl, Short Acting Methylphenidate, mixed salts amphetamine, Dyanavel XR.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cns-stimulant.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

CNS Stimulant — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CNS Stimulant (CNS Stimulant) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CNS stimulant. Area: Neurology / Psychiatry.

marketed CNS stimulant Neurology / Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

CNS Stimulant (CNS Stimulant) — Milton S. Hershey Medical Center. CNS stimulants increase the activity of the central nervous system by enhancing the release or blocking the reuptake of neurotransmitters such as dopamine and norepinephrine.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CNS Stimulant TARGET	CNS Stimulant	Milton S. Hershey Medical Center	marketed	CNS stimulant
methylphenidate HCl (Concerta)	methylphenidate HCl (Concerta)	Massachusetts General Hospital	marketed	Sympathomimetic amine; CNS stimulant	Dopamine transporter (DAT); Norepinephrine transporter (NET)
Adderall ® Immediate Release	Adderall ® Immediate Release	NYU Langone Health	marketed	Sympathomimetic amine; CNS stimulant	Dopamine transporter (DAT); Norepinephrine transporter (NET)
SODAS methylphenidate HCl	SODAS methylphenidate HCl	Massachusetts General Hospital	marketed	Sympathomimetic amine; CNS stimulant	Dopamine transporter (DAT); Norepinephrine transporter (NET)
Short Acting Methylphenidate	Short Acting Methylphenidate	BRC Operations Pty. Ltd.	marketed	Sympathomimetic amine; CNS stimulant	Dopamine transporter (DAT); Norepinephrine transporter (NET)
mixed salts amphetamine	mixed salts amphetamine	Rush University Medical Center	marketed	Sympathomimetic amine; CNS stimulant	Dopamine transporter (DAT); Norepinephrine transporter (NET)
Dyanavel XR	Dyanavel XR	Rochester Center for Behavioral Medicine	marketed	Sympathomimetic amine; CNS stimulant	Dopamine transporter (DAT); Norepinephrine transporter (NET)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CNS stimulant class)

Milton S. Hershey Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CNS Stimulant — Competitive Intelligence Brief. https://druglandscape.com/ci/cns-stimulant. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing